R. Lavieri

发表

Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity.

Sarah A. Scott, C. Lindsley, M. Armstrong, 2009, Bioorganic & medicinal chemistry letters.

Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program

Nicole M. Zaleski, Jana K. Shirey-Rice, Rebecca N. Jerome, 2018, Targeted Oncology.

Machine learning on drug-specific data to predict small molecule teratogenicity.

Andrew Beam, D. Aronoff, M. Shen, 2020, Reproductive toxicology.

Machine learning on drug-specific data to predict small molecule teratogenicity

D. Aronoff, M. Shen, R. Lavieri, 2019, bioRxiv.

Design, Synthesis and Biological Evaluation of Halogenated N- (2-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8- yl)ethylbenzamides: Discovery of an Isoform-Selective Small Molecule Phospholipase D2 (PLD2) Inhibitor

Sarah A. Scott, S. Jadhav, C. Lindsley, 2011 .

Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.

Sarah A. Scott, Sydney L. Stoops, C. Lindsley, 2009, Bioorganic & medicinal chemistry letters.

Medication history-wide association studies for pharmacovigilance of pregnant patients

D. Aronoff, S. V. Van Driest, J. A. Goldstein, 2022, Communications Medicine.

EHRs could clarify drug safety in pregnant people

D. Aronoff, J. Pulley, L. Bastarache, 2020, Nature Medicine.

Phospholipase D: enzymology, functionality, and chemical modulation.

C. Lindsley, H. Brown, R. Lavieri, 2011, Chemical reviews.

Binding Studies of Type I , II , and III Kinase Inhibitors against Bcr-Abl Kinase using BackScattering Interferometry : A Tale of Allostery

R. Isaacs, Stephen Dotson, R. Lavieri, 2015 .

Systematically Prioritizing Candidates in Genome-Based Drug Repurposing

Judith T. Lewis, Nicole M. Zaleski, Jana K. Shirey-Rice, 2019, Assay and drug development technologies.

Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.

Sarah A. Scott, S. Jadhav, C. Lindsley, 2010, Journal of medicinal chemistry.

Discovery of Desketoraloxifene Analogues as Inhibitors of Mammalian, Pseudomonas aeruginosa, and NAPE Phospholipase D Enzymes

Sarah A. Scott, Kyle A. Brown, C. Lindsley, 2014, ACS chemical biology.

Ethical Considerations in the Communication of Unexpected Information with Clinical Implications

R. Lavieri, S. Garner, 2006, The American journal of bioethics : AJOB.

Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study

Dana M. Brantley-Sieders, H. Hamm, J. Pulley, 2020, Molecular Cancer Therapeutics.

When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data.

Rebecca N Jerome, Leslie J Crofford, Nicole M. Zaleski, 2017, Assay and drug development technologies.

Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials.

Lisa H. Merck, I. Douglas, Akram Khan, 2023, JAMA.

Walk before you run: Feasibility challenges and lessons learned from the PROCLAIM study, a multicenter randomized controlled trial of misoprostol for prevention of recurrent C. difficile during COVID-19.

Nicole M. Zaleski, Jana K. Shirey-Rice, Rebecca N. Jerome, 2023, Anaerobe.

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

Nicole M. Zaleski, Jana K. Shirey-Rice, Rebecca N. Jerome, 2021, Frontiers in Genetics.

Clinical trial emulation can identify new opportunities to enhance the regulation of drug safety in pregnancy.

D. Aronoff, S. V. Van Driest, X. Niu, 2021, medRxiv.

The Ethical Mouse: Be Not Like Icarus

R. Lavieri, 2007, The American journal of bioethics : AJOB.

Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data.

Nicole M. Zaleski, Anup P Challa, Robert R Lavieri, 2020, Annual review of pharmacology and toxicology.

Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics.

Lisa Bastarache, Joshua C Denny, Dan M Roden, 2017, Assay and drug development technologies.

Allostery: Abl kinase and TruBind? Back-scattering Interferometry

R. Lavieri, 2015 .